Please login to the form below

Not currently logged in
Email:
Password:

Hospira CEO joins board of Kythera

Michael Ball named director of aesthetic medicine specialist

Kythera Michael BallKythera Biopharmacueticals has appointed Hospira's CEO Michael Ball to the company's board of directors.

Ball has served as CEO at Hospira, creators of the first biosimilar to be launched in the EU, since 2011.

He joined the company following a 16-year stint at Botox developers Allergan, serving as president from 2006. His earlier roles at Allergan included president of pharmaceuticals and president for North America.

This experience in aesthetic products such as Botox will serve him well in his role at Kythera, with the company currently developing ATX-101 as an injectable treatment for the reduction of fat under the chin and around the neck. The drug is currently in phase III development.

"We are thrilled to have him on board,” commented Keith Leonard, Kythera's president and CEO. “His knowledge and perspective will support our mission to bring innovation to the growing area of aesthetic medicine."

2nd October 2013

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics